If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00821535","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"N/A","arm_groups":[{"arm_group_label":"Active group","arm_group_description":"maraviroc dosing group","arm_type":"Other"}],"assignment":"Single Group","brief_summary":"To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg maraviroc in healthy male Japanese volunteers.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Human Immunodeficiency Virus (HIV) Infection","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:06:01","criteria":"Inclusion Criteria: - Healthy male Japanese subjects between the ages of 21 and 50 years inclusive. - Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg. Exclusion Criteria: - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). - Positive result for HIV, Hepatitis B surface antigen (HbsAg) or HCV antibody. - Hypersensitivity/allergic reactions to any component of maraviroc, including soy lecithin.","detailed_description":"","display_gender":"Male","display_gender_internal":"GENDER_MALE","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"12","exclusion":"","gender":"Male","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"26e3a010-7167-55f0-9b9f-efc5aab5e8e8","internal":{"content":null,"contentDigest":"001647fce7c53a23a18409e0bdd4602f","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Healthy male Japanese subjects between the ages of 21 and 50 years inclusive. - Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg. Exclusion Criteria: - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). - Positive result for HIV, Hepatitis B surface antigen (HbsAg) or HCV antibody. - Hypersensitivity/allergic reactions to any component of maraviroc, including soy lecithin.","interventions":[{"arm_group_label":"Active group","intervention_description":"12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.","intervention_name":"maraviroc (Selzentry, Celsentri)","intervention_type":"Drug"}],"interventional_subtype":"Other","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["pharmacokinetics, Japanese, healthy volunteer, maraviroc"],"last_follow_up_date":"05/01/2009 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001084&StudyName=Investigation%20Of%20Safety%20And%20Pharmacokinetics%20Following%20A%20Single%20Oral%20Dose%20Of%20300%20Mg%20Maraviroc%20In%20Healthy%20Male%20Japanese%20Volunteers"},{"description":"Link to ClinicalStudyResults.org","url":"http://www.clinicalstudyresults.org/drugdetails/?study_name=A4001084&sort=c.company_name&page=1&drug_id=10130"}],"locations":[{"City":"Singapore","Latitude":"1.301171","CountryDisplay":"Singapore","Longitude":"103.857198","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"188770","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open","maximum_age_raw":"50 Years","maximum_age":"50","minimum_age":"21","minimum_age_raw":"21 Years","modified_date":"10/01/2018 22:55:15","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers","org_study_id":"A4001084","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"PHASE 1","primary_compl_date":"05/01/2009 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Plasma and urine maraviroc concentrations for pharmacokinetic analysis","outcome_time_frame":"pre-48 hrs post dose","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Adverse event monitoring","outcome_time_frame":"Day 0 to Day 3","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Bood pressure, pulse rate","outcome_time_frame":"Day 0, Day 1, and Day 3","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Blood and urine safety laboratory tests","outcome_time_frame":"Day 0 and Day 3","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"ECG","outcome_time_frame":"Day 0 and Day 3","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"02/01/2009 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":false}},"pageContext":{"studyId":"A4001084"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}